Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study

EuroMRD, EuroClonality-NGS Working Group, Vincent H. J. van der Velden*, Monika Brueggemann, Giovanni Cazzaniga, Blanca Scheijen, Bastiaan Tops, Jan Trka, Karol Pal, Sonja Haenzelmann, Grazia Fazio, Simona Songia, Anton W. Langerak, Nikos Darzentas

*Corresponding author for this work

Research output: Contribution to journalArticleProfessionalpeer-review

4 Citations (Scopus)
14 Downloads (Pure)
Original languageEnglish
Pages (from-to)924-928
Number of pages5
JournalLeukemia
Volume35
Issue number3
Early online dateFeb 2021
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

Funding Information:
Acknowledgements GC was supported by a grant from the Italian Association for Cancer Research (AIRC), grant IG2015-17593. BS was supported by a grant from the Dutch Cancer Society (2017/ 11137).

Funding Information:
Conflict of interest The EuroClonality-NGS Working Group is an independent scientific subdivision of EuroClonality that aims at innovation, standardization and education in the field of diagnostic clonality analysis. The revenues of the previously obtained patent (PCT/NL2003/000690), which is collectively owned by the Euro-Clonality Foundation and licensed to InVivoScribe, are exclusively used for EuroClonality activities, such as for covering costs of the Working Group meetings, collective WorkPackages and the Euro-Clonality Educational Workshops. The EuroClonality consortium operates under an umbrella of ESLHO, which is an official EHA Scientific Working Group. VHJvdV: contract research for Pfizer and Janssen, Service Level Agreements with BD Biosciences and Agilent. MB reports personal fees from Incyte (advisory board), financial support for reference diagnostics from Affimed, Amgen and Regen-eron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), personal fees from Janssen (speakers bureau), personal fees from Molecular Health (advisory board), all outside the submitted work. AWL: contract research for Roche-Genentech, research support from Gilead, advisory board for AbbVie, speaker for Gilead, Janssen. The other authors declare no conflict of interest.

Research programs

  • EMC OR-01

Cite this